Imagine a world where diseases like cancer, cystic fibrosis, and hemophilia could be cured by precisely editing our genes. It sounds like science fiction, but it’s closer to reality than you might think. A groundbreaking $2 million grant from the National Institutes of Health (NIH) is propelling University of Hawaiʻi at Mānoa researcher Jesse Owens and his team toward this revolutionary goal. But here’s where it gets controversial: unlike widely known methods like CRISPR, which involve cutting DNA and risk unintended mutations, Owens’ approach promises a safer, more precise alternative—one that replaces genes without ever breaking the DNA strand. Could this be the future of gene therapy? And this is the part most people miss: the potential to apply this technology across a wide range of diseases, not just one. This isn’t just about curing a single illness; it’s about building a universal tool that could transform medicine.
Published on November 6, 2025, by UH News, this story highlights Owens’ ambitious project at the John A. Burns School of Medicine (JABSOM). Owens, an associate professor in the Department of Cell and Molecular Biology, calls this grant his “dream project.” Why? Because it funds his lab’s passion: developing gene-editing tools that are both safer and more precise than anything currently available. The four-year R01 award focuses on refining transposases, specialized enzymes that insert genes into exact locations in the genome—without the risks associated with DNA-cutting methods.
But how does it work? Owens’ team, led by graduate student Chris Tran, has spent years meticulously testing over 200 mutated enzymes to find the perfect candidate—one that makes minimal mistakes and targets only the intended genes. Their next challenge? Boosting the system’s “on-target” efficiency, ensuring genes land exactly where they’re supposed to. “We’ve minimized the off-target effects,” Owens explains. “Now, we’re fine-tuning the system to make it both incredibly safe and incredibly effective.”
The progress so far is staggering. Early versions of the technology had less than 1% efficiency, but after years of refinement, the latest iteration reaches nearly 100%. Owens admits, “We didn’t realize how fine-tuned this system needed to be. Even a slight shift of two base pairs could drastically reduce efficiency. It took hundreds of iterations to get it right.”
What makes Owens’ lab truly unique is its “disease agnostic” approach. Instead of focusing on one condition, they’re building tools that could tackle everything from hemophilia to cancer. Owens reflects, “Imagine starting something during your PhD and seeing it become part of a therapy that fights cancer. That’s what drives us.” This broad applicability is made possible by the grant’s unique structure, which isn’t tied to a specific disease area. Once perfected, the tool can be shared with researchers specializing in various illnesses.
One of the most exciting applications? Accelerating CAR T immunotherapy, which reprograms immune cells to attack cancer. Owens’ team plans to test the system in human T-cells before collaborating with clinical researchers. “The idea that this could one day help actual patients is what keeps us going,” he says.
The grant also supports two JABSOM graduate students, offering them hands-on experience at the cutting edge of gene therapy research. JABSOM Dean Sam Shomaker praises Owens’ work, saying, “Dr. Owens and his team are not only advancing the science of gene editing but inspiring the next generation of scientists who will carry forward our legacy of innovation.”
But here’s the question we leave you with: As gene-editing technology advances, how do we balance its incredible potential with ethical concerns about altering the human genome? Share your thoughts in the comments—we’d love to hear your perspective. For more details, visit JABSOM’s full story here.
